Skip to main content

Table 1 Patients’ baseline clinical characteristics

From: Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression

Characteristics n (%)
Median age (rang)(years) 53 (36–67)
FIGO stage
IIIA 1 (2.44%)
IIIB 3 (7.32%)
IIIC 33 (80.48%)
IV 4 (9.76%)
ECOG PS
0 31 (75.61%)
1 6 (14.63%)
2 4 (9.76%)
Histology type
High-grade serous carcinoma 29 (70.73%)
Low-grade serous carcinoma 9 (21.95%)
Mucinous carcinoma 2 (4.88%)
Endometrioid carcinoma 1 (2.44%)
Debulking surgery
Optimal 14 (34.15%)
Suboptimal 27 (65.85%)
Biochemical recurrence
Yes 19 (46.34%)
No 22 (53.66%)
Previous chemotherapy lines
1–2 29 (70.73%)
3–5 12 (29.27%)
Treatment regimen
Combined chemotherapy 13 (31.71%)
Monotherapy 28 (68.29%)
  1. FIGO, International Federation of Gynecology and Obstetrics; ECOG PS, Eastern Cooperative Group Performance Status